Compare YPF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YPF | ROIV |
|---|---|---|
| Founded | 1977 | 2014 |
| Country | Argentina | United Kingdom |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0B | 25.1B |
| IPO Year | 1995 | 2021 |
| Metric | YPF | ROIV |
|---|---|---|
| Price | $55.28 | $41.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $45.67 | $28.94 |
| AVG Volume (30 Days) | 1.0M | ★ 7.9M |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $14.39 | N/A |
| Revenue Next Year | N/A | $744.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.82 | $13.83 |
| 52 Week High | $57.49 | $42.50 |
| Indicator | YPF | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 68.78 | 66.10 |
| Support Level | $48.64 | $33.15 |
| Resistance Level | $56.82 | N/A |
| Average True Range (ATR) | 1.71 | 1.37 |
| MACD | 0.48 | 0.53 |
| Stochastic Oscillator | 97.74 | 78.11 |
YPF SA is an Argentina-based integrated oil and gas company. The company operates through four business segments: Upstream, Midstream and Downstream, LNG and Integrated Gas, and New Energies. The Upstream segment focuses on the exploration and production of crude oil and natural gas. The Midstream and Downstream segment includes refining, transportation, and commercialization of crude oil, refined, and petrochemical products. The LNG and Integrated Gas segment is involved in natural gas transportation, processing, storage, and commercialization. The New Energies segment focuses on energy transition initiatives, including natural gas distribution, power generation, renewable energy, and related technology development. It generates majority of revenue from Midstream and Downstream segment.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.